Modeling the impact of the 13-valent pneumococcal conjugate vaccine serotype catch-up program using United States claims data

Abstract

BackgroundAnalysis of US claims data from April 2010 to June 2011 estimated that 39% of the 13-valent pneumococcal conjugate vaccine (PCV13) catch-up eligible cohort would ever receive the catch-up vaccination; a previous analysis assumed 87%.MethodsThis updated figure was applied to a previously published 10-year Markov model while holding all other inputs constant.ResultsOur model estimated that the catch-up program as currently implemented is estimated to prevent an additional 1.7 million cases of disease in children aged ≤59 months over a 10-year period, compared with routine PCV13 vaccination with no catch-up program.ConclusionsBecause 39% catch-up uptake is less than the level of completion of the 4-dose primary PCV13 series, vaccine-preventable cases of pneumococcal disease and related deaths could be decreased further with additional uptake of catch-up vaccination in the catch-up eligible cohort.

Twenty-Year Public Health Impact of 7- and 13-Valent Pneumococcal Conjugate Vaccines in US Children

“…The efficacy of PCV7 (and later PCV13) against all forms of pneumococcal disease was greater than expected, partly because of indirect protection gained through herd immunity ( 6 – 8 ). The United States was the first country to introduce a PCV program for infants and, during the transition to PCV13, recommended the largest catch-up program for children <5 years of age who had been vaccinated with PCV7 ( 9 ). After an initially slow uptake limited by constrained supply, the United States has achieved consistently high (>80%) 3-dose coverage since 2005 ( 10 ).…”

Introduction of the 13-valent pneumococcal conjugate vaccine in an isolated pneumococcal vaccine-naïve indigenous population

“…Possibly, this recommendation needs to be extended to indigenous children. The importance of adequate antibody concentrations in children ⩾24 months lies in the establishment of herd immunity [12], since there is a large pneumococcal reservoir in Warao children aged ⩾24 months [1]. However, it is difficult to define adequate antibody concentrations.…”